Sinocelltech Group

Sinocelltech Group Equity

The The Equity of Sinocelltech Group (688520.SS) as of Oct 26, 2026 is 128.28 M CNY. In the previous year, The Equity was 140.90 M CNY — a change of -8.96% (lower).

Equity

128.28 MCNY

YoY

-8.96%

Last updated:

In 2025, Sinocelltech Group's equity was 128.28 M CNY, a -8.96% increase from the 140.90 M CNY equity in the previous year.

The Sinocelltech Group Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-22.36 M CNY
Jan 1, 2019
36.30 M CNY
Jan 1, 2020
590.83 M CNY
Jan 1, 2021
-226.51 M CNY
Jan 1, 2022
-236.65 M CNY
Jan 1, 2023
-599.46 M CNY
Jan 1, 2024
140.90 M CNY
Jan 1, 2025
128.28 M CNY
The Sinocelltech Group Equity history
YEAREquityYoY
128.28 MCNY-8.96%
140.90 MCNY-123.50%
-599.46 MCNY+153.31%
-236.65 MCNY+4.48%
-226.51 MCNY-138.34%
590.83 MCNY+1,527.81%
36.30 MCNY-262.29%
-22.36 MCNY-112.75%
175.44 MCNY+110.39%
83.39 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sinocelltech Group Stock analysis

What does Sinocelltech Group do? Sinocelltech Group Ltd, based in Beijing, China, operates in the Health Care sector with a focus on biotechnology. The company develops and manufactures biopharmaceutical products, including monoclonal antibodies, recombinant proteins, and vaccines. Key products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000, and SCT630. Sinocelltech employs 1,868 full-time staff and is listed on the stock market since June 22, 2020. It also engages in asset leasing and payment collection services. Sinocelltech Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Sinocelltech Group's Equity

Sinocelltech Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Sinocelltech Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Sinocelltech Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Sinocelltech Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Sinocelltech Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Sinocelltech Group stock

The Equity of Sinocelltech Group is 128.28 M CNY in 2025.

The Equity of Sinocelltech Group changed from 140.90 M CNY to 128.28 M CNY, representing a -8.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Sinocelltech Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Sinocelltech Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Sinocelltech Group

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Sinocelltech Group